Search
Neuropace Inc
NPCEAdd to Watchlist
15.630USD
+0.470+3.10%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
524.77MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Neuropace Inc is 8.50, ranking 28 out of 203 in the Healthcare Equipment & Supplies industry. The average price target is 18.00, with a high of 20.00 and a low of 15.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
20.000
Target Price
+27.96%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
94
Total
3
Median
7
Average
Company name
Ratings
Analysts
Neuropace Inc
NPCE
8
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
30
Thermo Fisher Scientific Inc
TMO
30
1
2
3
...
19
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Neuropace Inc's expected revenue for the next quarter?
Neuropace Inc's expected revenue is 22.60M.
What is Neuropace Inc's price target?
Analysts forecast that Neuropace Inc's price target is USD 18.00, with the highest forecast at USD 20.00 and the lowest forecast at USD 15.00.
How have Neuropace IncNPCE's recent earnings per share performed?
The market expectation was USD -0.20, while Neuropace IncNPCE's earnings per share (EPS) for the previous quarter was USD -0.08. EPS for the next quarter is expected at USD -0.21.
What is the analyst rating for Neuropace Inc?
Based on the ratings of Neuropace Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
